This study is a 40-week, blinded, placebo-controlled extension of Study TRCA-301
(NCT03317444). Eligible subjects who complete the 12-week treatment period in Study TRCA-301
have the option to participate in this extension study evaluating the long-term safety and
durability of effect of TRC101 in subjects with non-dialysis dependent chronic kidney disease
and metabolic acidosis. Eligible subjects will be treated with TRC101 or placebo once daily
(QD) on an out-patient basis for the subsequent 40 weeks. Subjects will continue to receive
the same blinded treatment (TRC101 or placebo) that they received in Study TRCA-301.